Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Beuzeboc

Showing results (121-130 of 132) with videos related to

Pageof 14
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 30, 2000
ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapyA Vincent-Salomon, M Carton, P Freneaux, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|August 28, 2012
[5 alpha-reductase inhibitors and prostate cancer: a statement of the Committee of Cancerology of the French Association of Urology]P Eschwège, N Gaschignard, G Ploussard, et al.
The Journal of Urology|August 21, 2002
Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer CentersB Escudier, J P Droz, F Rolland, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 4, 2014
[CCAFU Recommendations 2013: Prostate cancer]L Salomon, C Bastide, P Beuzeboc, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 17, 2016
[CCAFU french national guidelines 2016-2018 on prostate cancer]F Rozet, C Hennequin, J-B Beauval, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2024
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomesY Loriot, D P Petrylak, A Rezazadeh Kalebasty, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|May 4, 2021
Corrigendum to "French ccAFU guidelines-update 2020-2022: Prostate cancer" [Prog. Urol 30 (12 S) (2020), pp S136-S251]F Rozet, P Mongiat-Artus, C Hennequin, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|December 22, 2020
[French ccAFU guidelines - update 2020-2022: prostate cancer]F Rozet, P Mongiat-Artus, C Hennequin, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 16, 2019
[French ccAFU guidelines - Update 2018-2020: Prostate cancer]F Rozet, C Hennequin, J-B Beauval, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 6, 2018
RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate French ccAFU guidelines – Update 2018–2020: Prostate cancerF Rozet, C Hennequin, J-B Beauval, et al.
Pageof 14

Showing results (121-130 of 132) with videos related to

Sort By:
Pageof 14
European Journal of Cancer (Oxford, England : 1990)|March 30, 2000
ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapyA Vincent-Salomon, M Carton, P Freneaux, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|August 28, 2012
[5 alpha-reductase inhibitors and prostate cancer: a statement of the Committee of Cancerology of the French Association of Urology]P Eschwège, N Gaschignard, G Ploussard, et al.
The Journal of Urology|August 21, 2002
Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer CentersB Escudier, J P Droz, F Rolland, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 4, 2014
[CCAFU Recommendations 2013: Prostate cancer]L Salomon, C Bastide, P Beuzeboc, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 17, 2016
[CCAFU french national guidelines 2016-2018 on prostate cancer]F Rozet, C Hennequin, J-B Beauval, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2024
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomesY Loriot, D P Petrylak, A Rezazadeh Kalebasty, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|May 4, 2021
Corrigendum to "French ccAFU guidelines-update 2020-2022: Prostate cancer" [Prog. Urol 30 (12 S) (2020), pp S136-S251]F Rozet, P Mongiat-Artus, C Hennequin, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|December 22, 2020
[French ccAFU guidelines - update 2020-2022: prostate cancer]F Rozet, P Mongiat-Artus, C Hennequin, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 16, 2019
[French ccAFU guidelines - Update 2018-2020: Prostate cancer]F Rozet, C Hennequin, J-B Beauval, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 6, 2018
RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate French ccAFU guidelines – Update 2018–2020: Prostate cancerF Rozet, C Hennequin, J-B Beauval, et al.
Pageof 14